Drug Discovery Today
FEBRUARY 4, 2022
• Face-to-face event, taking place in London, UK, 26-27th April, will feature two dedicated tracks: ‘Scientific’, focused on seven core therapy areas and ‘Life Sciences Business’ Programme features keynote from George Freeman MP, with an update on the UK Government Life Sciences VisionRegistration for BioTrinity 2022 now available online
Drug Channels
FEBRUARY 1, 2022
The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Expenditure (NHE) data, which measures all U.S. spending on healthcare. (See links below.) These data provide our first official look at how the pandemic has affected U.S. healthcare spending. Today, I examine the key insights from these latest figures.
Drug Patent Watch
FEBRUARY 3, 2022
This chart shows the drugs with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Serbia? appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Development Group
FEBRUARY 1, 2022
Start Up, New Molecular Entities (NME) and New Chemical Entities (NCE) are high quality, affordable products that improve the quality of life for their patients. However, this often is associated with austere conditions wherein time and funds are both in short supply. Effective and consistent compilation of NME & NCE Product and Process Development for inclusion in the electronic submission can reduce costs and timelines.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Discovery Today
FEBRUARY 2, 2022
Data shows SARS-CoV-2 human challenge studies are safe in healthy young adults
Drug Channels
FEBRUARY 4, 2022
Today’s guest post comes from Jeff Berkowitz, CEO of advisory firm Real Endpoints. Jeff describes problems with Medicare copays that reduce adherence and persistence among seniors. He then describes RE Assist , Real Endpoints’ tech-enabled solution with key information on foundations for more than 30 diseases. To learn more about Medicare copayments and how the RE Assist solution helps patients, register to view Real Endpoints’ free webcast: Solving the Medicare Co-pay Dilemma.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
EG Life Sciences
FEBRUARY 2, 2022
In response to the pressing need to speed up delivery and improve lives, Eliassen Group and EG Life Sciences have been working closely with experts in a range of fields to explore the impact of Agile project management on biopharma. We have been inviting these experts to Lean Coffees to share their perspectives and answer questions from those who want to improve their processes.
NIH Director's Blog: Drug Development
FEBRUARY 1, 2022
The NIH continues to support the development of some very innovative therapies to control SARS-CoV-2, the coronavirus that causes COVID-19. One innovative idea involves a molecular decoy to thwart the coronavirus. How’s that? The decoy is a specially engineered protein particle that mimics the 3D structure of the ACE2 receptor , a protein on the surface of our cells that the virus’s spike proteins bind to as the first step in causing an infection.
Broad Institute
JANUARY 31, 2022
Homepage By admin January 31, 2022 Watch now Broad is accelerating discovery Broad Institute is a multidisciplinary community of researchers on a mission to improve human health. About us Latest Our community Join Broad We are a research organization dedicated to better understanding the roots of disease and narrowing the gap between new biological insights and impact for patients.
Drug Patent Watch
FEBRUARY 4, 2022
Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-six patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Policy Prescription
JANUARY 31, 2022
This post should serve as the beginning of a serious inquiry into the failure of U.S. state boards of pharmacy to properly regulate pharmacies that irresponsibly and too often illegally profited from opioid drug sales to patients. Sociologist Elizabeth Chiarello writes , “Boards have a duty to protect the public, but because they are mostly comprised of professionals whose common interests may conflict with those of the public, their ability to do so is questionable.
Drug & Device Law
JANUARY 31, 2022
A little more than six months ago (June 21, 2021), the United States District Court for the District of New Jersey began enforcing its Local Rule 7.1.1, requiring disclosure of third-party litigation funding. Local Rule 7.1.1 provides: Within 30 days of filing an initial pleading or transfer of the matter to this district, including the removal of a state action, or promptly after learning of the information to be disclosed, all parties, including intervening parties, shall file a statement (se
Broad Institute
JANUARY 31, 2022
Directory By admin January 31, 2022 Breadcrumb Home Directory Type the name of the person you're searching for.
Drug Patent Watch
FEBRUARY 3, 2022
Annual Drug Patent Expirations for SPIRIVA+RESPIMAT Spiriva Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are seven…. The post New patent expiration for Boehringer Ingelheim drug SPIRIVA RESPIMAT appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
FEBRUARY 3, 2022
Annual Drug Patent Expirations for RESTASIS Restasis is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are ten patents protecting…. The post New patent for Allergan drug RESTASIS appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 3, 2022
Annual Drug Patent Expirations for RESTASIS+MULTIDOSE Restasis Multidose is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are ten patents…. The post New patent for Allergan drug RESTASIS MULTIDOSE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 3, 2022
Annual Drug Patent Expirations for CYTALUX Cytalux is a drug marketed by On Target Labs and is included in one NDA. The generic ingredient in CYTALUX is pafolacianine sodium. Additional…. The post New patent for On Target drug CYTALUX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 2, 2022
This chart shows the drugs with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
FEBRUARY 2, 2022
Annual Drug Patent Expirations for DRIZALMA+SPRINKLE Drizalma Sprinkle is a drug marketed by Sun Pharma Global and is included in one NDA. It is available from one supplier. There are…. The post New patent for Sun Pharma drug DRIZALMA SPRINKLE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 2, 2022
Annual Drug Patent Expirations for LIVMARLI Livmarli is a drug marketed by Mirum and is included in one NDA. The generic ingredient in LIVMARLI is maralixibat chloride. Additional details are…. The post New patent for MIRUM drug LIVMARLI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 2, 2022
Annual Drug Patent Expirations for AURYXIA Auryxia is a drug marketed by Keryx Biopharms and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent expiration for Keryx Biopharms drug AURYXIA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
This chart shows the drugs with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for BIKTARVY Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are thirteen…. The post New patent expiration for Gilead Sciences drug BIKTARVY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for GENVOYA Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are thirteen…. The post New patent expiration for Gilead Sciences drug GENVOYA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for DESCOVY Descovy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are six…. The post New patent expiration for Gilead Sciences drug DESCOVY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for SYMTUZA Symtuza is a drug marketed by Janssen Prods and is included in one NDA. It is available from one supplier. There are ten patents…. The post New patent expiration for Janssen Prods drug SYMTUZA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for VEMLIDY Vemlidy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are four…. The post New patent expiration for Gilead Sciences drug VEMLIDY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are six…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for ODEFSEY Odefsey is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are ten…. The post New patent expiration for Gilead Sciences drug ODEFSEY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 31, 2022
This chart shows the pharmaceutical companies with the most patents in Slovenia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Slovenia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 30, 2022
Fesoterodine fumarate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Zydus Pharms, and Pfizer and, and is included…. The post New tentative approval for Amneal Pharms drug fesoterodine fumarate appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 30, 2022
This chart shows the pharmaceutical companies with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 29, 2022
This chart shows the pharmaceutical companies with the most emulsion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most emulsion dosed drugs…. The post Which pharmaceutical companies have the most emulsion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
113 
Let's personalize your content